Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
SEK 38.4
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Biosergen AB, a biopharmaceutical company, engages in the development of antifungal products. It is developing BSG005, an antifungal drug candidate for the treatment of life threatening invasive fungal diseases. The company was founded in 2004 and is headquartered in Solna, Sweden.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Data is available to registered users only
Buy
Sell